The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma

Cholangiocarcinoma (CCA) is one of the most difficult to treat cancers, and its nature of being largely refractory to most, if not all, current treatments results in generally poor prognosis and high mortality. Efficacious alternative therapies that can be used ubiquitously are urgently needed. Usin...

Descripción completa

Detalles Bibliográficos
Autores principales: Suppramote, Orawan, Prasopporn, Sunisa, Aroonpruksakul, Satinee, Ponvilawan, Ben, Makjaroen, Jiradej, Suntiparpluacha, Monthira, Korphaisarn, Krittiya, Charngkaew, Komgrid, Chanwat, Rawisak, Pisitkun, Trairak, Okada, Seiji, Sampattavanich, Somponnat, Jirawatnotai, Siwanon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157389/
https://www.ncbi.nlm.nih.gov/pubmed/35664774
http://dx.doi.org/10.3389/fonc.2022.877194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157389/
https://www.ncbi.nlm.nih.gov/pubmed/35664774
http://dx.doi.org/10.3389/fonc.2022.877194

Ejemplares similares